Clinical Biostatistics & Data Analysis

Designing PK/PD Substudies Within Phase I–III Clinical Trials The design of pharmacokinetic (PK) and pharmacodynamic (PD) substudies is crucial for the successful conduct of clinical trials across Phases I to III. Understanding the intricate relationships between drug exposure and response enables clinical research organizations (CROs) to maximize the therapeutic potential of new treatments while ensuring…

Read More “Designing PK/PD Substudies Within Phase I–III Clinical Trials” »

PK/PD and Exposure-Response Modeling in Clinical Development Strategy PK/PD and Exposure-Response Modeling in Clinical Development Strategy The complex landscape of clinical development necessitates robust methodologies to ensure the safety and efficacy of new therapies. Pharmacokinetics (PK) and Pharmacodynamics (PD), combined with exposure-response modeling, offer strategic frameworks for understanding drug behavior and response. This step-by-step tutorial…

Read More “PK/PD and Exposure-Response Modeling in Clinical Development Strategy” »

Visualizing PK/PD and Exposure-Response for Non-Statisticians Visualizing PK/PD and Exposure-Response for Non-Statisticians In the realm of clinical trials, understanding pharmacokinetics (PK), pharmacodynamics (PD), and exposure-response relationships is paramount. This tutorial aims to equip clinical operations, regulatory affairs, and medical affairs professionals with essential knowledge for visualizing and interpreting PK/PD data, particularly for individuals without a…

Read More “Visualizing PK/PD and Exposure-Response for Non-Statisticians” »

Handling Sparse and Rich PK Sampling in Global Clinical Trials Handling Sparse and Rich PK Sampling in Global Clinical Trials Introduction to Pharmacokinetics and Clinical Trials Pharmacokinetics (PK) is a vital component in the development and regulation of pharmaceuticals. It describes the absorption, distribution, metabolism, and excretion (ADME) of drugs within the body, providing critical…

Read More “Handling Sparse and Rich PK Sampling in Global Clinical Trials” »

Nonlinear Mixed-Effects Models: Practical Considerations for Teams Nonlinear mixed-effects models (NLME) have become a cornerstone of pharmacokinetic (PK), pharmacodynamic (PD), and exposure-response modeling in clinical trials. As such, a strong understanding of these models is essential for clinical operations, regulatory affairs, and medical affairs professionals involved in clinical trial solutions. This article outlines a step-by-step…

Read More “Nonlinear Mixed-Effects Models: Practical Considerations for Teams” »

Model-Based Dose Finding in Oncology, Rare Disease and Pediatrics In the realm of clinical trials and drug development, particularly within oncology, rare diseases, and pediatrics, model-based dose finding stands as a fundamental approach to determining optimal drug dosages while minimizing patient risk. This systematic method incorporates pharmacokinetics (PK) and pharmacodynamics (PD) principles, enabling researchers and…

Read More “Model-Based Dose Finding in Oncology, Rare Disease and Pediatrics” »

Integrating PK/PD Outputs Into Clinical and Regulatory Decision-Making Integrating PK/PD Outputs Into Clinical and Regulatory Decision-Making As the clinical research landscape continues to evolve, the integration of pharmacokinetic (PK) and pharmacodynamic (PD) outputs into clinical and regulatory decision-making has become critical. This is especially true for organizations conducting innovative clinical trials such as sanofi clinical…

Read More “Integrating PK/PD Outputs Into Clinical and Regulatory Decision-Making” »

PK/PD Considerations in DCT, Home Dosing and Remote Sampling PK/PD Considerations in DCT, Home Dosing and Remote Sampling Pharmacokinetics (PK) and pharmacodynamics (PD) play vital roles in clinical trials, particularly within the evolving landscape of decentralized clinical trials (DCTs). With the advent of remote sampling and home dosing, clinical operations must ensure that data quality…

Read More “PK/PD Considerations in DCT, Home Dosing and Remote Sampling” »

Integrating Biomarkers and Translational Data Into Exposure-Response Models In the evolving landscape of clinical trials, the integration of biomarkers and translational data into exposure-response (ER) models is becoming increasingly critical. This comprehensive guide focuses on the methodologies and regulatory guidelines for clinical operations, regulatory affairs, and medical affairs professionals in the US, UK, and EU….

Read More “Integrating Biomarkers and Translational Data Into Exposure-Response Models” »